KMDA

SEC filing KMDA Receives FDA Approval for In-House Rabies Virus Neutralization Testing Laboratory, Expands Testing Capabilities for KEDRAB and KAMRAB Products

1d ago

SEC filing KMDA Reports $45.2M Revenue, $4.1M Net Income, $0.07 EPS, Guides $200-205M 2026

20d ago

SEC filing KMDA FDA Approves San Antonio Plasma Center, 50K Liters Capacity, $8-10M Revenue

68d ago

SEC filing KMDA Reports $0 Revenue, $0 EPS, No Deals, No Growth Metrics

76d ago

SEC filing KMDA Declares $0.25 Cash Dividend, $14.4M Payout, Record FY2025 Revenue & Profitability

83d ago

News Kamada forecasts double-digit profitable growth in 2026

145d ago